Histogenics Corporation to Present at Upcoming Industry Conferences
May 16 2017 - 8:30AM
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative
medicine company focused on developing and commercializing products
in the musculoskeletal space, today announced that Management will
be presenting at several upcoming industry conferences.
- 12th World Advanced Therapies & Regenerative
Medicine Congress – London, England (May 17-19, 2017)
Adam Gridley, Histogenics’ CEO, will be participating in several
panels discussing regulatory strategies and capital raising and for
regenerative medicine companies. With over 600 participants,
200 speakers and 7 tracks of content, the congress is a vibrant
platform for knowledge sharing in the areas of stem cells, gene
therapy, T-cell receptors and gene editing.
A presentation “Hybrid US/Japanese Clinical and Regulatory
Strategies” is scheduled for Wednesday, May 17th, where Mr. Gridley
will share the Company’s experience working with the Japanese
regulatory authorities for Histogenics’ lead cell therapy product
NeoCart. Additionally, Mr. Gridley will be hosting a plenary
roundtable discussion regarding “Analytical Considerations for
Cellular Therapy Manufacturing” on Wednesday, May 17th.
Lastly, a presentation “Public Market Fundraising for
Regenerative Medicine Companies” is scheduled for Thursday, May
18th.
- Alliance for Regenerative Medicine Cell and Gene
Exchange – Washington, DC (May 22-23, 2017)
Stephen Kennedy, Histogenics’ CTO, will be participating on a
panel on Tuesday, May 23rd discussing promising cell and gene
therapy programs. The Cell & Gene Exchange is a
partnering meeting focused on bringing together the regulatory,
business and patient advocacy communities.
In conjunction with this meeting, Mr. Kennedy will also
participate in a meeting of the Standards Coordinating Body for
Gene, Cell and Regenerative Medicines and Cell-based Drug Discovery
(SCB). The SCB is a multi-stakeholder consortium in the cell
and gene therapy sector working to support the development,
dissemination, education and implementation of relevant standards
and related deliverables via public-private partnerships and
ongoing work with national and international consensus standards
organizations. The SCB’s goal is to serve as a source of
information, knowledge, experience and data collection related to
process, material and reference standards to enable more efficient
and successful development, manufacture and testing of advanced
therapies and cell-based drug discovery. Mr. Kennedy was
asked to join this committee in the first quarter of 2017 by the
Alliance for Regenerative Medicine.
- Forum for Innovative Regenerative Medicine (FIRM) –
Regenerative Medicine Crossroad® #4 Conference – Tokyo, Japan (June
1, 2017)
Adam Gridley, Histogenics’ CEO, will be presenting a corporate
overview including Histogenics’ recent progress negotiating a
regulatory pathway for NeoCart in Japan. The event is
sponsored by the Regenerative Medicine Industrialization Tactical
Committee of FIRM, and is designed to facilitate partnering and
licensing discussions between innovative companies and Japanese
regenerative medical companies in Japan.
About Histogenics
Corporation
Histogenics is a leading regenerative medicine
company developing and commercializing novel tissue therapies that
may offer more rapid and durable recoveries for patients with pain
and loss of function due to musculoskeletal conditions.
Histogenics’ regenerative medicine platform combines expertise in
cell processing, scaffolding, tissue engineering and bioadhesives
to create tissue ex-vivo. Histogenics’ first investigational
product candidate, NeoCart is designed to treat cartilage defects
in the knee and is currently in Phase 3 clinical development.
NeoCart is designed to exhibit characteristics of articular,
hyaline cartilage prior to and upon implantation into the knee and
therefore does not rely on the body to make new cartilage. As
a result, NeoCart is the only product in development or on the
market with a one-year primary superiority endpoint as compared to
the standard of care. There are more than 500,000 or more
knee cartilage procedures in the United States each year, with many
healthy active adults avoiding treatment as they seek other
alternatives. Left untreated, even a small cartilage defect
can expand in size and progress to debilitating osteoarthritis,
ultimately necessitating a joint replacement procedure.
Osteoarthritis is more common in adults over the age of 50,
but the condition and precursors of the condition can be observed
much earlier, and cartilage damage is believed to be one of the
leading contributors of this disease. For more information,
please visit www.histogenics.com.
Contact:
Investor Relations
Tel: +1 (781) 547-7909
InvestorRelations@histogenics.com
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From Apr 2023 to Apr 2024